Skip to main content
NPJ Breast Cancer logoLink to NPJ Breast Cancer
. 2024 Feb 5;10:13. doi: 10.1038/s41523-024-00619-5

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Alessandra Fabi 1,, Luisa Carbognin 2, Andrea Botticelli 3, Ida Paris 2, Paola Fuso 2, Maria Cristina Savastano 4, Nicla La Verde 5, Carla Strina 6, Rebecca Pedersini 7, Stefania Guarino 8, Giuseppe Curigliano 9,10, Carmen Criscitiello 9,10, Mimma Raffaele 11, Alessandra Beano 12, Antonio Franco 13, Maria Rosaria Valerio 14, Francesco Verderame 15, Andrea Fontana 16, Eva Regina Haspinger 17, Alessia Caldara 18, Alba Di Leone 13, Giampaolo Tortora 19,20, Diana Giannarelli 21, Giovanni Scambia 2,22
PMCID: PMC10844213  PMID: 38316819

Correction to: npj Breast Cancer 10.1038/s41523-023-00579-2, published online 08 September 2023

In this article the author name Paola Fuso was incorrectly written as Paolo Fuso. The original article has been corrected.


Articles from NPJ Breast Cancer are provided here courtesy of Nature Publishing Group

RESOURCES